Mississippi sues pharmaceutical company

Jul 25, 2006

Mississippi has filed a legal action against Eli Lilly and Co. alleging a plan to defraud the state of millions of dollars in Medicaid reimbursements.

The lawsuit involves the "off-label" uses of the anti-psychotic drug Zyprexa, the Jackson (Miss.) Clarion Ledger reported.

The suit alleges representatives of Eli Lilly persuaded Mississippi doctors to prescribe the drug to patients suffering from conditions such as anxiety, mood swings and disturbed sleep when the drug is only approved to treat bipolar disorder and schizophrenia.

Tim Balducci, Mississippi special assistant attorney general, told the Clarion Ledger Eli Lilly targeted Mississippi because the state's Medicaid system cannot determine when a medication is prescribed for non-approved uses.

The Indianapolis-based Eli Lilly has 30 days to respond to the suit.

Copyright 2006 by United Press International

Explore further: CKD, glomerulonephritis risk higher for those with psoriasis

add to favorites email to friend print save as pdf

Related Stories

Mississippi sues pharmaceutical company

Jul 25, 2006

Mississippi has filed a legal action against Eli Lilly and Co. alleging a plan to defraud the state of millions of dollars in Medicaid reimbursements.

Recommended for you

Older women restrict driving more than older men

4 hours ago

(HealthDay)—Older women restrict their driving activity more than older men, regardless of physical health or cognitive status, according to a study published in the November issue of the Journal of th ...

Sublingual immunotherapy tablet safe in asthma patients

5 hours ago

(HealthDay)—For individuals with asthma and allergic rhinitis with/without conjunctivitis (AR/C), treatment with a Timothy grass sublingual immunotherapy tablet (SLIT-tablet) seems safe, according to research ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.